Vivo Bio Tech has scheduled its 39th Annual General Meeting for Wednesday, September 30, 2026, at 3:00 pm. The meeting will be conducted via Video Conferencing or Other Audio Visual Means.

Shareholders will vote on ordinary business items, including the adoption of audited financial statements for FY26 and the re-appointment of Mr. Kalyan Ram Mangipudi as a director by rotation. The agenda also features special business resolutions regarding the re-appointment of two Whole-time Directors.

Director Re-Appointments

The Board seeks shareholder approval to re-appoint Mr. Sri Kalyan Kompella as Whole-time Director for five years, from November 3, 2026, to November 2, 2031. His consolidated monthly salary is proposed at ₹2,50,000. The Board holds the authority to revise his gross salary by up to 50% per annum.

Additionally, shareholders must approve a special resolution to re-appoint Dr. Sankaranarayanan Alangudi as Whole-time Director for five years, from January 6, 2027, to January 5, 2032. Dr. Alangudi, aged 83, requires this special resolution under Section 196(3)(a) of the Companies Act, 2013. His monthly salary is set at ₹1,00,000.

Financial Performance Context

The explanatory statement highlights a shift in financial performance for FY26 compared to the prior year. Total income rose slightly to ₹5,300.93 crore from ₹5,147.74 crore in FY25. However, Profit Before Tax contracted sharply to ₹458.26 crore from ₹908.11 crore. This decline resulted in a net loss of ₹193.61 crore in FY26, reversing the net profit of ₹757.08 crore recorded in FY25.

What the Numbers Show

The divergence between top-line growth and bottom-line performance indicates significant margin compression. While revenue increased, the pre-tax profit fell by nearly half, driven by what the company cites as subdued market demand and intense competition leading to low product pricing. The transition from a substantial profit to a net loss underscores the pressure on profitability despite modest income gains.

Meeting Logistics

Remote e-voting will be available from September 27, 2026, at 9:00 am until September 29, 2026, at 5:00 pm. The cut-off date for shareholding eligibility is September 23, 2026. Members holding shares in physical form or demat mode can vote through the Central Depository Services (India) Limited platform. Physical attendance is not permitted.

Promoter group entity Maxcell Communication India Private Limited has transferred 12,00,000 equity shares of Vivo Bio Tech Limited off-market on August 21, 2026. The transaction marks the complete exit of the promoter affiliate from the company, reducing its stake to nil.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Gangireddy Suresh, Director at Maxcell Communication, signed the intimation submitted to the BSE and the listed entity.

Shareholding Changes

Prior to the transfer, Maxcell Communication held 12,00,000 equity shares, representing 5.41% of the total voting capital and 4.09% of the diluted voting capital. The entity had no encumbrances, warrants, or convertible securities associated with this holding.

Following the off-market transfer, the promoter group entity’s holding stands at Nil. There were no changes to the company’s total equity share capital or diluted share capital as a result of this inter-se transfer.

Capital Structure Context

Vivo Bio Tech’s total equity share capital remains at 2,21,90,628 equity shares of ₹10 each, aggregating to ₹22,19,06,280. The total diluted share capital is calculated at 2,93,23,111 equity shares. This diluted figure assumes the conversion of 6,27,409 pending convertible equity warrants and the exercise of 63,22,000 outstanding ESOPs.

What the Numbers Show

The complete divestment by a promoter group entity suggests a consolidation of holdings within the promoter circle or a strategic restructuring of interests. With Maxcell Communication exiting entirely, the voting power previously held by this specific entity is likely consolidated elsewhere within the promoter group, though the filing does not specify the recipient of the transferred shares.